Randomized, double-blind, placebo-controlled, sequential-group, ascending single dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of IMA-638 administered subcutaneously and intravenously to subjects with asthma
Phase of Trial: Phase I
Latest Information Update: 21 Mar 2014
At a glance
- Drugs Anrukinzumab; Anrukinzumab
- Indications Asthma
- Focus Adverse reactions
- 24 Jul 2007 Status changed from recuiting to completed.
- 07 Oct 2006 New trial record.